Publications by authors named "Mari Eriksson"

Claim this Profile
D
Diabetic myonecrosis complicated by emphysematous pyomyositis and abscess caused by Escherichia coli: a case report.
Anne M Kerola, Kari K Eklund, Heikki Valleala, Olli Tynninen, Jaakko Helve, Mari Eriksson

J Med Case Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of ETVAX®, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: a double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West Africa.
Anu Kantele, Marianna Riekkinen, T Sakari Jokiranta, Sari H Pakkanen, Jukka-Pekka Pietilä, Mari Eriksson

J Travel Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superspreading of SARS-CoV-2 Omicron BA.2.23 among vaccinated Finnish adults: symptomatic COVID-19 only contracted by those without recent infection.
Marianna Riekkinen, Mikael Kajova, Mari Eriksson, Annika Luukkainen, Ville Holmberg

Epidemiol Infect· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and evaluation of the incidence of cryptococcosis in Finland 2004-2018.
Anne Toivonen, Mari Eriksson, Nathalie Friberg, Timo Hautala, Sohvi Kääriäinen

Infect Dis (Lond)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in adult liver transplant recipients.
Mari Eriksson, Helena Käyhty, Mika Lahdenkari, Heikki Mäkisalo, Veli-Jukka Anttila

Vaccine· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.
Mari Eriksson, Helena Käyhty, Heikki Saha, Mika Lahdenkari, Petri Koskinen

Transpl Infect Dis· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
Mari Eriksson, Janne J Jokinen, Sanni Söderlund, Pekka Hämmäinen, Jyri Lommi

Transpl Infect Dis· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases.
Esko Tavast, Tamara Tuuminen, Sari H Pakkanen, Mari Eriksson, Anu Kantele

Int J Rheumatol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis